Strategic FDA & International Regulatory Solutions
For global pharma, medical device, biologics, and combination product leaders facing FDA scrutiny.
• FORMER FDA DIRECTOR OF INVESTIGATIONS
• GLOBAL REMEDIATION AND INSPECTION READINESS
• STRATEGIC DEFENSE FOR 483S & WARNING LETTERS
DRUG | MEDICAL DEVICE | BIOLOGICS | COMBINATION PRODUCTS | BIMO CLINICAL TRIALS
Built for VPs of Quality, Regulatory, and Site Heads managing complex global portfolios.
High-Impact Global Regulatory & Quality Strategy
End-to-End Recovery
Leading corporate-wide remediation for global life science leaders, transforming critical compliance failures into sustainable, market-ready operational excellence.
- For sites and networks under intense regulatory pressure
- Stabilize operations while executing sustainable remediation
Enforcement Action Defense
Providing C-suite counsel on 483 and Warning Letter responses to mitigate legal risks, restore agency trust, and prevent costly market withdrawal or injunction.
- For organizations responding to 483s, Warning Letters, or Consent Decrees
- Shape a credible, defensible strategy grounded in FDA expectations
Audit & Site Readiness
Ensuring success for PAI and routine inspections through expert auditing, staff coaching, and risk-based prep for FDA and Global Notified Body expectations.
- For global manufacturing and clinical sites preparing for PAI or routine inspections
- Run mock inspections, close gaps, and align teams on inspection behavior
Submission Excellence
Accelerating market access with technical review and strategy for PMA, 510(k), NDA, ANDA and BLA filings, optimized for rapid approval and global compatibility.
- For regulatory and technical teams preparing complex submissions
- Strengthen files with risk-based, regulator-ready documentation
Modern Quality Ecosystems
Designing scalable quality architectures including Design Controls, Data Integrity, and CAPA systems that drive compliance and accelerate innovation cycles.
- For leaders modernizing QMS, data integrity, and digital quality systems
- Design scalable architectures that support growth and global oversight
Executive Risk
Integrating ISO 14971 and ICH Q9 standards with business objectives to provide senior leaders with transparency, decision-making clarity, and lasting corporate resiliency.
- For boards, CEOs, and senior executives managing enterprise regulatory risk
- Clarify risk exposure and prioritize decisive, board-level actions
Leverage Elite FDA Agency Insights
Specialized Expertise by Product Class
Pharmaceuticals
Medical Devices
Combination Products
Biologics
Bioresearch Monitoring (BIMO)
Deep technical command across diverse modalities, ensuring your global regulatory roadmap is as sophisticated as the breakthrough science it protects.
Deep experience across CDER, CDRH, CBER, and BIMO inspections and enforcement trends.
Examples: global sterile injectables network, high-risk implantables, and cell & gene therapies.